Latest Earnings Results: Q2 '26
Estimated EPS
$0.32
Reported EPS
$0.31
Surprise
-3.12%
Estimated Rev
$114.34M
Reported Rev
$113.04M
Surprise
-1.14%
$IRWD Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.31 up 106.67% YoY • Reported revenue of $113.04M up 32.62% YoY • Ironwood Pharmaceuticals raised its 2026 full-year financial guidance, now expecting U.S. LINZESS net sales of $1.15 to $1.20 billion, total revenue of $460 to $485 million, and adjusted EBITDA greater than $310 million.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | $0.32 | -- | -- | N/A |
Q2 '26 | $0.32 | $0.31 | -3.12% | MISSED |
Q1 '26 | $0.25 | $0.24 | -2.70% | MISSED |
Q4 '25 | -$0.06 | -$0.01 | 84.62% | BEAT |
Q3 '25 | $0.11 | $0.23 | 117.51% | BEAT |